Linker Information
General Information of This Linker
| Linker ID |
LIN0PVIFI
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
T800
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C27H37N5O6
|
|||||
| Isosmiles |
CN[C]c1cc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)C=CC2=O)C(C)C)ccc1CO
|
|||||
| InChI |
InChI=1S/C27H37N5O6/c1-17(2)25(31-22(34)8-6-5-7-13-32-23(35)11-12-24(32)36)27(38)29-18(3)26(37)30-21-10-9-19(16-33)20(14-21)15-28-4/h9-12,14,17-18,25,28,33H,5-8,13,16H2,1-4H3,(H,29,38)(H,30,37)(H,31,34)/t18-,25-/m0/s1
|
|||||
| InChIKey |
LWMKNYXUYFYLFC-BVZFJXPGSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
527.622
|
Polar area
|
156.94
|
||
|
Complexity
|
527.2743839
|
xlogp Value
|
0.85459
|
|||
|
Heavy Count
|
38
|
Rot Bonds
|
15
|
|||
|
Hbond acc
|
7
|
Hbond Donor
|
5
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
AMT-562 [Phase 1]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.80% (Day 28) | Low HER3 expression (HER3+) | ||
| Method Description |
AMT-562 (10 mg/kg, day 1) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PDX-200930) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 40) | Low HER3 expression (HER3+) | ||
| Method Description |
AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
|
||||
| In Vivo Model | Squamous cell carcinoma PDX model (PDX: PDX-361318) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 49) | Low HER3 expression (HER3+) | ||
| Method Description |
AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PDX-361319) | ||||
References